On 29 October 2026, all 53 Member States of the WHO European Region unanimously adopted the Region’s first Roadmap for action on artificial intelligence in health. Covering 2026–2033, the roadmap establishes a common regional approach centred on governance, lifecycle oversight, data quality, interoperability, cybersecurity, workforce capability and real-world evaluation.
The roadmap is not pharmaceutical GMP guidance, but it is important for pharmaceutical companies because AI used in clinical development, digital health, real-world evidence, patient-support technologies and post-market activities increasingly operates inside the same health-system infrastructure that the roadmap is intended to govern.
The European Medicines Agency has published a detailed description of how it intends to govern artificial intelligence inside the European medicines regulatory network. Published on 11 November 2026, the new EMA resource describes use-case-specific AI risk assessment, technical guardrails, multidisciplinary oversight and a policy framework intended to support a transition toward AI-enabled regulatory work under human supervision by 2030.
For pharmaceutical companies, this is important even though the framework governs EMA’s own AI use: it shows how one of the world’s most influential medicines regulators is translating high-level AI principles into operational controls.
Artificial intelligence is increasingly being introduced not only by pharmaceutical companies, but also by regulatory authorities. A new IFPMA position paper, published on 9 November 2026, examines what responsible use should look like when AI supports regulatory review, scientific assessment, inspections, document preparation and other authority activities.
The paper’s central message is important for pharmaceutical companies: AI can improve regulatory capacity and efficiency, but human regulatory judgement, protection of sponsor data, source verification and accountability must remain central.
How often do pharmaceutical regulators actually identify artificial intelligence as a GMP compliance problem? A recent analysis of 3,011 FDA Warning Letters found only one direct CGMP violation involving AI. But evidence from the UK, Switzerland, Japan, Europe and other regulatory authorities reveals a more complex picture: inspectors are already encountering AI-related failures, while regulatory expectations are developing faster than publicly reported enforcement cases.
On 2 November 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) published new principles for the responsible use of artificial intelligence in regulatory activities. The document explicitly includes generative AI and covers regulatory judgment and decision-making throughout the pharmaceutical lifecycle, including manufacturing and post-marketing activities.